These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 25248882

  • 1. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.
    He SZ, Busfield S, Ritchie DS, Hertzberg MS, Durrant S, Lewis ID, Marlton P, McLachlan AJ, Kerridge I, Bradstock KF, Kennedy G, Boyd AW, Yeadon TM, Lopez AF, Ramshaw HS, Iland H, Bamford S, Barnden M, DeWitte M, Basser R, Roberts AW.
    Leuk Lymphoma; 2015 May; 56(5):1406-15. PubMed ID: 25248882
    [Abstract] [Full Text] [Related]

  • 2. Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123(+)/CD131(-) phenotype of leukemia stem cells.
    Gao C, Leyton JV, Schimmer AD, Minden M, Reilly RM.
    Appl Radiat Isot; 2016 Apr; 110():1-7. PubMed ID: 26748017
    [Abstract] [Full Text] [Related]

  • 3. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
    Hutmacher C, Volta L, Rinaldi F, Murer P, Myburgh R, Manz MG, Neri D.
    Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
    [Abstract] [Full Text] [Related]

  • 4. CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice.
    Williams BA, Wang XH, Leyton JV, Maghera S, Deif B, Reilly RM, Minden MD, Keating A.
    Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
    [Abstract] [Full Text] [Related]

  • 5. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
    Leyton JV, Williams B, Gao C, Keating A, Minden M, Reilly RM.
    Leuk Res; 2014 Nov; 38(11):1367-73. PubMed ID: 25278187
    [Abstract] [Full Text] [Related]

  • 6. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.
    Xie LH, Biondo M, Busfield SJ, Arruda A, Yang X, Vairo G, Minden MD.
    Blood Cancer J; 2017 Jun 02; 7(6):e567. PubMed ID: 28574487
    [Abstract] [Full Text] [Related]

  • 7. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A, Gillis D, Lewis I.
    J Hematol Oncol; 2016 Jul 27; 9(1):61. PubMed ID: 27465508
    [Abstract] [Full Text] [Related]

  • 8. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB.
    Cell Stem Cell; 2009 Jul 02; 5(1):31-42. PubMed ID: 19570512
    [Abstract] [Full Text] [Related]

  • 9. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
    Bergstrom D, Leyton JV, Zereshkian A, Chan C, Cai Z, Reilly RM.
    Nucl Med Biol; 2016 Oct 02; 43(10):635-41. PubMed ID: 27497632
    [Abstract] [Full Text] [Related]

  • 10. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
    Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Nogueras González GM, Cavazos A, Pan R, Mu H, Wang SA, Zhou J, Ai-Atrash G, Ciurea SO, Rettig M, DiPersio JF, Cortes J, Huang X, Kantarjian HM, Andreeff M, Ravandi F, Konopleva M.
    Clin Cancer Res; 2017 Jul 01; 23(13):3385-3395. PubMed ID: 28096272
    [Abstract] [Full Text] [Related]

  • 11. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
    Morgan MA, Kloos A, Lenz D, Kattre N, Nowak J, Bentele M, Keisker M, Dahlke J, Zimmermann K, Sauer M, Heuser M, Schambach A.
    Viruses; 2021 Jul 14; 13(7):. PubMed ID: 34372571
    [Abstract] [Full Text] [Related]

  • 12. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
    Habibi-Anbouhi M, Kafi Z, Ghazizadeh L, Kharazi S, Behdani M, Faraji F, Shokrgozar MA.
    Iran J Allergy Asthma Immunol; 2019 Oct 30; 18(6):679-687. PubMed ID: 32245312
    [Abstract] [Full Text] [Related]

  • 13. Effect of Compound Zhebei Granule () combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia.
    Wang J, Lai ZL, Chen XY, Li DY, Zhang YY, Ma W, Chu YT, Shi FQ, Yang L, Hou L.
    Chin J Integr Med; 2016 Jun 30; 22(6):438-44. PubMed ID: 26666761
    [Abstract] [Full Text] [Related]

  • 14. SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells.
    Wang M, Wu H, Duan M, Yang Y, Wang G, Che F, Liu B, He W, Li Q, Zhang L.
    Life Sci; 2019 Sep 01; 232():116663. PubMed ID: 31323275
    [Abstract] [Full Text] [Related]

  • 15. Development of a new anti-CD123 monoclonal antibody to target the human CD123 antigen as an acute myeloid leukemia cancer stem cell biomarker.
    Abdollahpour-Alitappeh M, Razavi-Vakhshourpour S, Abolhassani M.
    Biotechnol Appl Biochem; 2018 Nov 01; 65(6):841-847. PubMed ID: 29972607
    [Abstract] [Full Text] [Related]

  • 16. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.
    Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, Byrd JC, Lozanski G, Vasu S, Muthusamy N.
    Haematologica; 2018 Aug 01; 103(8):1288-1297. PubMed ID: 29773600
    [Abstract] [Full Text] [Related]

  • 17. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, Cribioli E, Maltese F, Galimberti S, Lopez AF, Biondi A, Bonnet D, Biagi E.
    Br J Haematol; 2013 May 01; 161(3):389-401. PubMed ID: 23432359
    [Abstract] [Full Text] [Related]

  • 18. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
    Arcangeli S, Rotiroti MC, Bardelli M, Simonelli L, Magnani CF, Biondi A, Biagi E, Tettamanti S, Varani L.
    Mol Ther; 2017 Aug 02; 25(8):1933-1945. PubMed ID: 28479045
    [Abstract] [Full Text] [Related]

  • 19. Soluble Expression and Characterization of a New scFv Directed to Human CD123.
    Moradi-Kalbolandi S, Davani D, Golkar M, Habibi-Anbouhi M, Abolhassani M, Shokrgozar MA.
    Appl Biochem Biotechnol; 2016 Apr 02; 178(7):1390-406. PubMed ID: 26749295
    [Abstract] [Full Text] [Related]

  • 20. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A, Pinto AD, Al-Zadjali S.
    Acta Haematol; 2017 Apr 02; 138(3):175-181. PubMed ID: 29065396
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.